<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089050</url>
  </required_header>
  <id_info>
    <org_study_id>1820.00</org_study_id>
    <secondary_id>FHCRC-1820.00</secondary_id>
    <secondary_id>CDR0000378021</secondary_id>
    <nct_id>NCT00089050</nct_id>
  </id_info>
  <brief_title>Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and&#xD;
      either kill them or deliver cancer-killing substances to them without harming normal cells.&#xD;
      Cyclosporine may increase the effectiveness of gemtuzumab ozogamicin by making cancer cells&#xD;
      more sensitive to the drug. Combining gemtuzumab ozogamicin with cyclosporine may kill more&#xD;
      cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving gemtuzumab ozogamicin together with&#xD;
      cyclosporine works in treating older patients with relapsed acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of gemtuzumab ozogamicin and cyclosporine, in terms of the&#xD;
           complete remission rate, in older patients with relapsed acute myeloid leukemia.&#xD;
&#xD;
        -  Determine the toxicity and pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate clinical response with laboratory studies of drug susceptibility in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive cyclosporine IV continuously over 72 hours on days 1-3 and 15-17.&#xD;
      Eight hours after initiation of each cyclosporine infusion, patients receive gemtuzumab&#xD;
      ozogamicin IV over 2 hours on days 1 and 15. Treatment continues in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25-50 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in terms of complete remission rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlate clinical response to laboratory studies of drug susceptibility</measure>
  </secondary_outcome>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemtuzumab ozogamicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Morphologically confirmed acute myeloid leukemia (AML) by bone marrow aspirate&#xD;
&#xD;
               -  More than 20% blasts by morphologic criteria&#xD;
&#xD;
               -  Relapsed disease ≥ 3 months after prior complete remission&#xD;
&#xD;
          -  Blasts CD33-positive by flow cytometry&#xD;
&#xD;
          -  No primary hematologic disorder that preceded initial presentation with AML&#xD;
&#xD;
          -  No documented secondary AML related to prior chemotherapy or toxin exposure&#xD;
&#xD;
          -  No acute promyelocytic leukemia (FAB M3)&#xD;
&#xD;
          -  Not a candidate for transplant therapy&#xD;
&#xD;
          -  No active CNS leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  60 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≤ 30,000/mm^3 (hydroxyurea allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or ALT ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not planning hematopoietic stem cell transplantation immediately after study therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Hematopoietic&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 1 month since prior investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No administration of any of the following for 24 hours after cyclosporine&#xD;
             administration:&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Metoclopramide&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Aminoglycosides&#xD;
&#xD;
               -  Amphotericin B&#xD;
&#xD;
               -  Vancomycin&#xD;
&#xD;
               -  Cimetidine&#xD;
&#xD;
               -  Ranitidine&#xD;
&#xD;
               -  Trimethoprim/sulfamethoxazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Fluconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Voriconazole&#xD;
&#xD;
               -  Carbamazepine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen H. Petersdorf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>November 28, 2011</last_update_submitted>
  <last_update_submitted_qc>November 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2011</last_update_posted>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

